These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 7528558)

  • 1. Prostate cancer trends in southeast Michigan 1973-1992.
    Demers RY
    In Vivo; 1994; 8(3):429-31. PubMed ID: 7528558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends.
    Telesca D; Etzioni R; Gulati R
    Biometrics; 2008 Mar; 64(1):10-9. PubMed ID: 17501937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of screening on prostate cancer rates and trends.
    Mettlin C
    Microsc Res Tech; 2000 Dec; 51(5):415-8. PubMed ID: 11074610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach.
    Etzioni R; Gulati R; Falcon S; Penson DF
    Med Decis Making; 2008; 28(3):323-31. PubMed ID: 18319508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interpreting recent trends in prostate cancer incidence and mortality.
    Gann PH
    Epidemiology; 1997 Mar; 8(2):117-20. PubMed ID: 9229198
    [No Abstract]   [Full Text] [Related]  

  • 6. Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
    Schröder FH
    Can J Urol; 2005 Feb; 12 Suppl 1():2-6; discussion 92-3. PubMed ID: 15780157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate carcinoma detection and increased prostate-specific antigen levels after 4 years in Dutch and Japanese males who had no evidence of disease at initial screening.
    Ito K; Raaijmakers R; Roobol M; Wildhagen M; Yamanaka H; Schröder FH
    Cancer; 2005 Jan; 103(2):242-50. PubMed ID: 15578715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening by prostate-specific antigen and digital rectal examination in relation to prostate cancer mortality. A case-control study.
    Walsh PC
    J Urol; 2005 Nov; 174(5):1824-5. PubMed ID: 16217296
    [No Abstract]   [Full Text] [Related]  

  • 9. Prostate cancer screening trends of New York State men at least 50 years of age, 1994 to 1997.
    McDavid K; Melnik TA; Derderian H
    Prev Med; 2000 Sep; 31(3):195-202. PubMed ID: 10964632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam.
    Roobol MJ; Grenabo A; Schröder FH; Hugosson J
    J Natl Cancer Inst; 2007 Sep; 99(17):1296-303. PubMed ID: 17728218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in baseline PSA levels in Japanese men from 1988 to 2003.
    Ohi M; Ito K; Yamamoto T; Miyakubo M; Takechi H; Kubota Y; Suzuki K
    Urology; 2008 Jul; 72(1):95-8. PubMed ID: 18455775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening for prostate cancer: updated experience from the Tyrol study.
    Horninger W; Berger A; Pelzer A; Klocker H; Oberaigner W; Schönitzer D; Severi G; Robertson C; Boyle P; Bartsch G
    Can J Urol; 2005 Feb; 12 Suppl 1():7-13; discussion 92-3. PubMed ID: 15780158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trends in prostate cancer incidence and mortality in New Mexico are consistent with an increase in effective screening.
    Gilliland F; Becker TM; Smith A; Key CR; Samet JM
    Cancer Epidemiol Biomarkers Prev; 1994 Mar; 3(2):105-11. PubMed ID: 8049631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate cancer and prostate-specific antigen (PSA) screening in Austria.
    Vutuc C; Schernhammer ES; Haidinger G; Waldhör T
    Wien Klin Wochenschr; 2005 Jul; 117(13-14):457-61. PubMed ID: 16091872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regular PSA screens undervalued, underutilized in prostate cancer detection.
    Healthc Demand Dis Manag; 2000 May; 6(5):70-2, 65. PubMed ID: 11383016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate cancer incidence and survival in relation to education (United States).
    Steenland K; Rodriguez C; Mondul A; Calle EE; Thun M
    Cancer Causes Control; 2004 Nov; 15(9):939-45. PubMed ID: 15577296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An evaluation of prostate-specific antigen as a screening test for prostate cancer.
    Dorr VJ; Williamson SK; Stephens RL
    Arch Intern Med; 1993 Nov; 153(22):2529-37. PubMed ID: 7694555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-systematic screening for prostate cancer in Sweden--survey from the National Prostate Cancer Registry.
    Stattin P; Johansson R; Damber JE; Hellström M; Hugosson J; Lundgren R; Varenhorst E; Johansson JE
    Scand J Urol Nephrol; 2003; 37(6):461-5. PubMed ID: 14675917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quebec prostate cancer mortality dropped in 1996.
    Meyer F; Moore L; Bairati I; Fradet Y
    Cancer Prev Control; 1998 Aug; 2(4):163-6. PubMed ID: 10093628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ten year trend in prostate cancer screening with high prostate-specific antigen exposure rate in Japan.
    Okihara K; Kitamura K; Okada K; Mikami K; Ukimura O; Miki T
    Int J Urol; 2008 Feb; 15(2):156-60; discussion 161. PubMed ID: 18269453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.